AMAG enters definitive merger contract with Allos Therapeutics AMAG Pharmaceuticals.

Additionally, the combined company will meet the requirements to receive double-digit, tiered royalties based on revenue in the partnered areas. Collaborations outside the U.S.S. 3Sbio and areas in China for FERAHEME, and Mundipharma International Company Limited for FOLOTYN Global development program expected to drive expanded market possibilities for both brands FERAHEME marketing applications are under review in the EU, Canada and Switzerland for the treating IDA in adult CKD patients; regulatory decisions expected in the EU and Canada in 2011 and in Switzerland in 2012 FERAHEME is being evaluated in a worldwide registrational system for a wide IDA indication; completion of enrollment expected by the end of 2011 FOLOTYN advertising application can be under review in the EU for the treating patients with relapsed or refractory PTCL; regulatory decision expected in the EU in early 2012 FOLOTYN will be evaluated in two global Phase 3 registrational studies discovering its activity in first-range PTCL and relapsed or refractory cutaneous T-cell lymphoma Related StoriesResearchers identify new target for novel immune-oncology treatmentsLilly expands existing immuno-oncology collaboration with AstraZenecaMirati to provide data on tyrosine kinase inhibitor at ESMO 2015 European Tumor Congress We are very worked up about this merger as it creates a mixed company with a sophisticated commercial presence in appealing marketplace segments backed by a more efficient organizational framework, stated Brian J.G.Entries were judged on quality, creativeness and resourcefulness and overall quality that serve as market benchmarks by a panel of worldwide marketing and communication experts. This full year, nearly 5, 000 entries were received from organizations including media Fortune and conglomerates 500 companies from all over the world.. Acucela begins phase 2b/3 clinical trial of emixustat hydrochloride to treat GA connected with dry AMD Acucela Inc., a clinical-stage biotechnology company focused on developing new treatments for sight threatening eye diseases, today announced that a phase 2b/3 medical trial investigating emixustat hydrochloride in subjects with geographic atrophy associated with dried out age-related macular degeneration has been initiated. AMD is the most common cause of irreversible vision reduction in the developed globe, the overwhelming most which is connected with dry AMD.